Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Glycemic control with empagliflozin, a novel selective SG... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
0
Authors
Bo-Wen Lin
9 more
Bo-Wen Lin
•
Nobutaka Koibuchi
7 more
•
Shokei Kim‐Mitsuyama
Published
October 25, 2014
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to review
Share your thoughts on this paper...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Cardiovascular Diabetology
Topics
Medicine
Internal Medicine
Endocrinology
Surgery
Nephrology
Show all topics
DOI
10.1186/s12933-014-0148-1
License
CC-BY
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Cardiovascular Diabetology
Topics
Medicine
Internal Medicine
Endocrinology
Surgery
Nephrology
Show all topics
DOI
10.1186/s12933-014-0148-1
License
CC-BY
Other Formats
PDF
